Clinical Trial Update: Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of talazoparib and temozolomide in advanced, rare cancers; the study is currently active but not recruiting. It encompa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Talzenna (talazoparib)
• Temodar (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING